Exact Mass: 370.2275
Exact Mass Matches: 370.2275
Found 207 metabolites which its exact mass value is equals to given mass value 370.2275,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Thromboxane B2
Thromboxanes. A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). -- Pubchem. Thromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Thromboxanes
6-Keto-prostaglandin F1a
6-keto-Prostaglandin F1a is the physiologically active and stable metabolite of prostacyclin. (A prostaglandin found in nearly all mammalian tissue that is a powerful vasodilator and inhibits platelet aggregation; it is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue; the sodium salt has been also used to treat primary pulmonary hypertension (Hypertension, Pulmonary). A delayed and prolonged increase in 6-keto-PGF1 alpha is reported in animals with septic shock, i.e., those with fecal peritonitis or cecal ligation. 6-keto-Prostaglandin F1a plasma levels has been found increased in patients with epidemic hemorrhagic fever, in patients with acute obstructive suppurative cholangitis, in patients with gynecologic cancer and has significant correlation with the level of high density lipoprotein cholesterol in plasma. (PMID 1976492, 2298410, 2379443, 2111556)Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 6-keto-Prostaglandin F1a is the physiologically active and stable metabolite of prostacyclin. (A prostaglandin found in nearly all mammalian tissue that is a powerful vasodilator and inhibits platelet aggregation; it is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue; the sodium salt has been also used to treat primary pulmonary hypertension (Hypertension, Pulmonary).
Octaethylene glycol
Octaethylene glycol, also known as 3,6,9,12,15,18,21-heptaoxatricosane-1,23-diol, is classified as a member of the polyethylene glycols. Polyethylene glycols are oligomers or polymers of ethylene oxide, with the general formula (C2H4O)n (with n>=3). Octaethylene glycol is considered to be practically insoluble (in water) and relatively neutral. (ChemoSummarizer)
20-Hydroxy-PGF2a
20-Hydroxy PGF2a is the omega-oxidation product of PGF2alpha via P450 omega-oxidation. Prostaglandin F2a (PGF2) is one of the earliest discovered and most common prostaglandins is actively biosynthesized in various organs of mammals and exhibits a variety of biological activities, including contraction of pulmonary arteries. PGF2 is mainly synthesized directly from PGH2 by PGH2 9,11-endoperoxide reductase. A small amount of PGF2 is also produced from PGE2 by PGE2 9-ketoreductase. A PGF2 epimer has been reported to exhibit various biological activities, and its levels are increased in bronchoalveolar lavage fluid, plasma, and urine in patients with mastocytosis and bronchial asthma. PGF2 is synthesized from PGD2 by PGD2 11-ketoreductase. (PMID: 16475787, 3473507) [HMDB] 20-Hydroxy PGF2a is the omega-oxidation product of PGF2alpha via P450 omega-oxidation. Prostaglandin F2a (PGF2) is one of the earliest discovered and most common prostaglandins is actively biosynthesized in various organs of mammals and exhibits a variety of biological activities, including contraction of pulmonary arteries. PGF2 is mainly synthesized directly from PGH2 by PGH2 9,11-endoperoxide reductase. A small amount of PGF2 is also produced from PGE2 by PGE2 9-ketoreductase. A PGF2 epimer has been reported to exhibit various biological activities, and its levels are increased in bronchoalveolar lavage fluid, plasma, and urine in patients with mastocytosis and bronchial asthma. PGF2 is synthesized from PGD2 by PGD2 11-ketoreductase. (PMID: 16475787, 3473507).
10,11-dihydro-20-dihydroxy-LTB4
10,11-dihydro-20-dihydroxy-LTB4 is formed when leukotriene B4 (LTB4) is metabolized by beta-oxidation.LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 8632343, 9667737). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 10,11-Dihydro-20-dihydroxy-LTB4 is formed when leukotriene B4 (LTB4) is metabolized by beta-oxidation.LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 8632343, 9667737)
Prostaglandin G1
Prostaglandin G1 belongs to the family of Prostaglandins. Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Prostaglandin G1 belongs to the family of Prostaglandins
19-hydroxyprostaglandin H1(1-)
19-hydroxyprostaglandin H1(1-) is considered to be practically insoluble (in water) and acidic
Adb-chminaca, (+/-)-
19-Hydroxyprostaglandin E1
19-Hydroxyprostaglandin F
N-[1'-(Aminocarbonyl)-2',2'-dimethylpropyl]-1-(cyclohexylmethyl)-1h-indazole-3-carboxamide
Aspidocarpine
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.694 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.691 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.688 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.689
1-epi-2beta,3beta,5beta,6beta,10alpha,16alpha-hexahydroxygrayanane|craiobiotoxin VII
1-acetyl-17-methoxy-aspidospermidin-16-ol|Aspidocarpin|aspidocarpine
17-methoxy-corynox-16-ene-16-carboxylic acid methyl ester|Rynchophyllin
TXB2-[d4]
CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0071.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0071.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID STD_neg_MSMS_1min0071.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001327.mzML; PROCESSING averaging of repeated ion fragments at 30.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001327.mzML; PROCESSING averaging of repeated ion fragments at 20.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001327.mzML; PROCESSING averaging of repeated ion fragments at 10.0 eV within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001327.mzML; PROCESSING averaging of repeated ion fragments at 40.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001327.mzML; PROCESSING averaging of repeated ion fragments at 30.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ] CONFIDENCE standard compound; NATIVE_RUN_ID QExHF03_NM_0001327.mzML; PROCESSING averaging of repeated ion fragments at 20.0 NCE within 5 ppm window [MS, MS:1000575, mean of spectra, ]
Octaethylene glycol
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 11 INTERNAL_ID 11; CONFIDENCE Reference Standard (Level 1)
Ala Ala Ile Pro
Ala Ala Leu Pro
Ala Ala Pro Ile
Ala Ala Pro Leu
Ala Ile Ala Pro
Ala Ile Pro Ala
Ala Leu Ala Pro
Ala Leu Pro Ala
Ala Pro Ala Ile
Ala Pro Ala Leu
Ala Pro Ile Ala
Ala Pro Leu Ala
Gly Pro Val Val
Gly Val Pro Val
Gly Val Val Pro
Ile Ala Ala Pro
Ile Ala Pro Ala
Ile Pro Ala Ala
Leu Ala Ala Pro
Leu Ala Pro Ala
Leu Pro Ala Ala
Pro Ala Ala Ile
Pro Ala Ala Leu
Pro Ala Ile Ala
Pro Ala Leu Ala
Pro Gly Val Val
Pro Ile Ala Ala
Pro Leu Ala Ala
Pro Val Gly Val
Pro Val Val Gly
Val Gly Pro Val
Val Gly Val Pro
Val Pro Gly Val
Val Pro Val Gly
Val Val Gly Pro
Val Val Pro Gly
20-Hydroxy-PGF2a
FA 20:3;O4
Thromboxane B2
A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.
Artilide
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
(3AR,4S,5R,6AS)-4-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)-5-((TETRAHYDRO-2H-PYRAN-2-YL)OXY)HEXAHYDRO-2H-CYCLOPENTA[B]FURAN-2-ONE
(Z)-(9S)-2-acetoxy-2-acetyl-5,9-dimethyl-10-hydroxydeca-4-enoic acid tert-butyl ester
butane-1,4-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid
butane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid
2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid
(E)-but-2-enoic acid,vinyl acetate,vinyl decanoate
tert-butyl 4-(2-oxospiro[cyclopentane-1,3-indole]-1-yl)piperidine-1-carboxylate
1,2-bis(ethenyl)benzene,1-ethenyl-4-ethylbenzene,4-methylphenol
ethenyl acetate,2-ethylhexyl prop-2-enoate,methyl 2-methylprop-2-enoate
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclohexyl-N-cyclopentyl- (9CI)
sn-Glycerol 3-phosphate biscyclohexylammonium salt
5-(7-(5-Hydro-4-ethyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole
20-Hydroxyprostaglandin E1
A prostaglandin E derivative that is prostaglandin E1 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.
Prostaglandin G1
A member of the class of prostaglandins G that is 9alpha,11alpha-epidioxy-13-trans-prostenoic acid carrying an additional hydroperoxy substituent at the 15S-position.
(S)-N-(4-Carbamimidoylbenzyl)-1-(3-Cyclopentylpropanoyl)pyrrolidine-2-Carboxamide
7-[2-[(E)-3,7-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]heptanoic acid
(E)-7-[2-[(E)-3,7-dihydroxyoct-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid
7-[6-[(E)-3,7-dihydroxyoct-1-enyl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]heptanoic acid
[3-Carboxy-2-(9-carboxy-3,4-dimethylidenenonanoyl)oxypropyl]-trimethylazanium
[3-carboxy-2-[(2E,10E)-11-carboxyundeca-2,10-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(7E,9E)-11-carboxyundeca-7,9-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(5E,9E)-11-carboxyundeca-5,9-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(3E,10E)-11-carboxyundeca-3,10-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(5E,8E)-11-carboxyundeca-5,8-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(6E,8E)-11-carboxyundeca-6,8-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(7E,10E)-11-carboxyundeca-7,10-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(5E,10E)-11-carboxyundeca-5,10-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(4E,9E)-11-carboxyundeca-4,9-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(2E,6E)-11-carboxyundeca-2,6-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(6E,9E)-11-carboxyundeca-6,9-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(4E,8E)-11-carboxyundeca-4,8-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(4E,10E)-11-carboxyundeca-4,10-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(3E,9E)-11-carboxyundeca-3,9-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(5E,7E)-11-carboxyundeca-5,7-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(8E,10E)-11-carboxyundeca-8,10-dienoyl]oxypropyl]-trimethylazanium
Ala-Leu-Ala-Pro
A tetrapeptide composed of L-alanine, L-leucine, L-alanine, and L-proline joined in sequence by peptide linkages.
19-Hydroxyprostaglandin H1
A prostaglandin H that consists of prostaglandin H1 bearing an additional hydroxy substituent at position 19.
(5Z,9E,12S,14Z)-8,11,12,20-tetrahydroxyicosa-5,9,14-trienoic acid
An icosanoid that is (5Z,9E,14Z)-icosa-5,9,14-trienoic acid carrying four hydroxy substituents at positions 8, 11, 12 and 20. An intermediary metabolite from the 12(R)-lipoxygenase pathway.
N-tert-butyl-2-[2-methoxy-4-[(2-phenylethylamino)methyl]phenoxy]acetamide
(5S,6Z,8E,12S,14Z)-5,12,20,20-tetrahydroxyicosa-6,8,14-trienoic acid
2-[Hydroxy-(2-hydroxy-3-octoxypropoxy)phosphoryl]oxyethyl-trimethylazanium
5-[7-[4-(4-Ethyl-4,5-dihydrooxazol-2-yl)phenoxy]heptyl]-3-methyl-isoxazole
(Z)-7-[(2R,3S,4S,6S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoic acid
6-Oxoprostaglandin F1alpha
A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.
